Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from pivotal global Phase 3 trial WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2025-- Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc.